Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.

Registrati

HOTH Hoth Therapeutics Inc

0,810886

0,03709 (4,79%)

Ultimo aggiornamento: 18:19:52

Dati in Delay di 15 minuti

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Grafico Azioni Hoth Therapeutics (NASDAQ:HOTH)
Storico
Da Mar 2025 a Apr 2025

Clicca qui per i Grafici di Hoth Therapeutics

Grafico Azioni Hoth Therapeutics (NASDAQ:HOTH)
Storico
Da Apr 2024 a Apr 2025

Clicca qui per i Grafici di Hoth Therapeutics

Notizie Hoth Therapeutics Inc - HOTH

Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform
Giovedì 17 Aprile 2025 (5 ore fa) • PR Newswire (US)

Form 8-K - Current report
Martedì 15 Aprile 2025 (2 giorni fa) • Edgar (US Regulatory)

Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial
Martedì 15 Aprile 2025 (2 giorni fa) • PR Newswire (US)

Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ
Mercoledì 2 Aprile 2025 (2 settimane fa) • PR Newswire (US)

Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aβ levels, within 20 hours
Mercoledì 2 Aprile 2025 (2 settimane fa) • PR Newswire (US)

Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage
Lunedì 31 Marzo 2025 (2 settimane fa) • PR Newswire (US)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Venerdì 28 Marzo 2025 (3 settimane fa) • Edgar (US Regulatory)

Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation
Mercoledì 26 Marzo 2025 (3 settimane fa) • PR Newswire (US)

Form 8-K - Current report
Martedì 25 Marzo 2025 (3 settimane fa) • Edgar (US Regulatory)

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment
Martedì 18 Marzo 2025 (1 mese fa) • PR Newswire (US)

Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need
Lunedì 10 Marzo 2025 (1 mese fa) • PR Newswire (US)

Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting
Mercoledì 5 Marzo 2025 (1 mese fa) • PR Newswire (US)

Più Hoth Therapeutics Inc Articoli Notizie

Enzolytics (PK)

Republic of Italy

BNP Paribas Issuance

180 Life Sciences

GPS Participacoes e Empr... ON

IT0005616013 20250602 8

Delayed Upgrade Clock

Assistenza: support@advfn.it

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni